Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
Valion Bio President, COO And CFO Lisa Wolf To Resign, Effective December 11
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
Valion Bio Announces That The Armed Forces Radiobiology Research Institute Will Evaluate The Therapeutic Efficacy Of Entolimod
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
Valion Bio Announces Final Data From Entolimod Study For Hematopoietic And Gastrointestinal Forms Of Acute Radiation Syndrome; AFRRI Study Found No Evidence Of Treatment-Related Toxicity After One Dose Of Entolimod, Supporting Advancement Toward A Fully Funded Therapeutic Study
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Valion Bio Confirms Receipt Of Proposed Acquisition Offers For Its Velocity Bioworks; Terms Undisclosed
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platform
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Valion Bio Regains NASDAQ Compliance
Valion Bio Announces Changes to Management and Board of Directors
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.